Tier 4 drugs and the fraying of the social compact

N Engl J Med. 2008 Jul 24;359(4):333-5. doi: 10.1056/NEJMp0804261.
No abstract available

MeSH terms

  • Biological Products / economics*
  • Biological Products / therapeutic use
  • Cost Allocation
  • Deductibles and Coinsurance*
  • Drug Costs / trends
  • Ethics, Medical
  • Health Care Costs / trends
  • Humans
  • Insurance Coverage / economics*
  • Insurance, Pharmaceutical Services / economics*
  • Prescription Fees
  • Reimbursement Mechanisms
  • Risk Sharing, Financial*
  • United States

Substances

  • Biological Products